Top in hem/onc: Phase 3 data on lung cancer therapy, new leadership at Mayo Clinic
Click Here to Manage Email Alerts
Results of the GEMSTONE-301 study showed that sugemalimab was well tolerated and effective in patients with stage III non-small cell lung cancer. It was the top story in hematology/oncology last week.
In other news, the Mayo Clinic announced its new executive director of cancer programs. This was another top story.
Read these and more in hematology/oncology below:
Sugemalimab extends PFS in stage III NSCLC
A randomized phase 3 study designed to evaluate sugemalimab (EQRx) as a treatment for stage III non-small cell lung cancer met its primary endpoint, according to a press release. Read more.
Mayo Clinic appoints executive director of cancer programs
Cheryl Willman, MD, has been named executive director of Mayo Clinic cancer programs. Willman also will serve as director of Mayo Clinic Comprehensive Cancer Center. Read more.
Health Equity Tracker assesses impact of COVID-19 on underserved populations
For a minority patients and other historically underrepresented populations, the COVID-19 pandemic has accentuated longstanding disparities in health care. Read more.
Sidney Kimmel Cancer Center — Jefferson Health names deputy director
Andrew E. Aplin, PhD, has been appointed deputy director for scientific strategy at Sidney Kimmel Cancer Center — Jefferson Health. Read more.
FDA grants priority review to pacritinib for myelofibrosis with severe thrombocytopenia
The FDA granted priority review to pacritinib for treatment of patients with myelofibrosis with severe thrombocytopenia, according to the agent’s manufacturer. Read more.